阿伐西他滨通过靶向骨肉瘤中的FoxM1-AKR1C1抑制肿瘤生长。
Avasimibe inhibits tumor growth by targeting FoxM1-AKR1C1 in osteosarcoma.
作者信息
Wang Liang, Liu Yang, Yu Guanzhen
机构信息
Department of Orthopedic, Changzheng Hospital, Shanghai 200003, China.
Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China,
出版信息
Onco Targets Ther. 2019 Jan 24;12:815-823. doi: 10.2147/OTT.S165647. eCollection 2019.
BACKGROUND
Osteosarcoma (OS) is a rare bone tumor with a high propensity for lung metastasis and poor patient outcomes. It is crucial to identify novel therapeutic strategies and biomarkers.
PATIENTS AND METHODS
ARK1C1 staining was detected in OS specimens, and its clinical significance was assessed. A potential AKR1C1 inhibitor, avasimibe, was used to target AKR1C1.
RESULTS
High expression of AKR1C1 was observed in OS and was associated with poor outcomes for patients with OS. Avasimibe was found to inhibit cell proliferation and tumor growth by reducing the expression of AKR1C1 and FoxM1 in vivo and in vitro.
CONCLUSION
These findings indicate that AKR1C1 is a promising prognostic factor and may serve as a novel therapeutic target of avasimibe for human OS.
背景
骨肉瘤（OS）是一种罕见的骨肿瘤，具有较高的肺转移倾向且患者预后较差。确定新的治疗策略和生物标志物至关重要。
患者与方法
检测骨肉瘤标本中的AKR1C1染色，并评估其临床意义。使用一种潜在的AKR1C1抑制剂阿伐司他来靶向AKR1C1。
结果
在骨肉瘤中观察到AKR1C1高表达，且与骨肉瘤患者的不良预后相关。发现阿伐司他在体内和体外均可通过降低AKR1C1和FoxM1的表达来抑制细胞增殖和肿瘤生长。
结论
这些发现表明，AKR1C1是一个有前景的预后因素，可能成为阿伐司他治疗人类骨肉瘤的新治疗靶点。
Zotero 插件